Back to Search
ANTOINETTE KAVANAUGH, PHD
PHD
Clinical Psychologist
NPI: 1063836831Individual
Specialties, Licenses & Credentials
Clinical PsychologistPrimary
Psychologist — Clinical
Code: 103TC0700X
71005870(IL)
Research & Publications (20)
Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results.
PMID 17644541·Ann Rheum Dis·2008
3-trial
Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.
PMID 17114188·Ann Rheum Dis·2007
3-trial
Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis.
PMID 16960923·J Rheumatol·2006
2-rct
Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis.
PMID 16096330·Ann Rheum Dis·2006
3-trial
The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year.
PMID 16439444·Ann Rheum Dis·2006
4-observational
Health economics: implications for novel antirheumatic therapies.
PMID 16239392·Ann Rheum Dis·2005
6-review
Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry.
PMID 19359261·Ann Rheum Dis·2010
4-observational
Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide.
PMID 19147616·Ann Rheum Dis·2010
4-observational
Infection prophylaxis in antirheumatic therapy: emphasis on vaccination.
PMID 19444117·Curr Opin Rheumatol·2009
6-review
The clinical efficacy of tocilizumab in rheumatoid arthritis.
PMID 19436841·Drugs Today (Barc)·2009
6-review
A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach.
PMID 19527820·J Am Acad Dermatol·2009
8-other
Perceptions of disease and health-related quality of life among patients with gout.
PMID 19307257·Rheumatology (Oxford)·2009
4-observational
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
PMID 19333944·Arthritis Rheum·2009
3-trial
Treatment disparity related to race/ethnicity and education in rheumatoid arthritis patients: comment on the article by Constantinescu et al.
PMID 19644891·Arthritis Rheum·2009
8-other
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.
PMID 19217154·Lancet·2009
4-observational
Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study.
PMID 19369454·J Rheumatol·2009
4-observational
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.
PMID 19015207·Ann Rheum Dis·2009
3-trial
Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.
PMID 19333948·Arthritis Rheum·2009
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 30 N MICHIGAN AVE, SUITE 1604
CHICAGO, IL 60602 - Phone
- (312) 726-2914
Quick Facts
- NPI
- 1063836831
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile